International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 5, Issue 6 | Opinion Article | Open Access DOI

Refining the Concept of Lupus-associated Nociplasticity: A Proposal to Subdivide Type 2 SLE Based on Therapeutic Response

Deepak Gupta^*

Deepak Gupta*, Imran Yousaf, Yasmin Bilal

Division of Rheumatology, Department of Medicine, Tidalhealth, Salisbury, MD, USA

^*Correspondence to: Deepak Gupta 

Abstract

Fibromyalgia-like symptoms occur commonly in patients with Systemic Lupus Erythematosus. In 2019, it was proposed that symptoms of Lupus should be characterized as Type 1 and Type 2. Type 1 symptoms such as arthritis, serositis and nephritis are responsive to immunomodulatory treatments and Type 2 symptoms such as fatigue, widespread pain, poor sleep and headache do not respond to anti-inflammatory and immunosuppressive medications. We propose that Type 2 symptoms be subclassified into type 2a and Type 2b as some Type 2 symptoms also respond to immunomodulatory and anti-inflammatory therapies.

Keywords:

Systemic Lupus Erythematosus; Lupus; Lupus associated nociplasticity

Citation:

Deepak Gupta, Imran Yousaf, Yasmin Bilal. Refining the Concept of Lupus-associated Nociplasticity: A Proposal to Subdivide Type 2 SLE Based on Therapeutic Response. Int Clinc Med Case Rep Jour. 2026;5(6):1-2.